CN112626163B - 一种评价敏感皮肤不适感的细胞学方法 - Google Patents
一种评价敏感皮肤不适感的细胞学方法 Download PDFInfo
- Publication number
- CN112626163B CN112626163B CN202011402345.1A CN202011402345A CN112626163B CN 112626163 B CN112626163 B CN 112626163B CN 202011402345 A CN202011402345 A CN 202011402345A CN 112626163 B CN112626163 B CN 112626163B
- Authority
- CN
- China
- Prior art keywords
- trpv1
- discomfort
- stimulus
- cells
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 230000037307 sensitive skin Effects 0.000 title claims abstract description 25
- 102000003566 TRPV1 Human genes 0.000 claims abstract description 33
- 101150016206 Trpv1 gene Proteins 0.000 claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 206010040830 Skin discomfort Diseases 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 9
- 239000000419 plant extract Substances 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 35
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 30
- 230000002380 cytological effect Effects 0.000 claims description 18
- 229960000448 lactic acid Drugs 0.000 claims description 18
- 238000011156 evaluation Methods 0.000 claims description 17
- 229960002504 capsaicin Drugs 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000017663 capsaicin Nutrition 0.000 claims description 14
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- 239000002085 irritant Substances 0.000 claims description 12
- 231100000021 irritant Toxicity 0.000 claims description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 229960005323 phenoxyethanol Drugs 0.000 claims description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- 229930002330 retinoic acid Natural products 0.000 claims description 6
- 229960004889 salicylic acid Drugs 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 108091005462 Cation channels Proteins 0.000 claims description 4
- 102000003563 TRPV Human genes 0.000 claims description 4
- 108060008564 TRPV Proteins 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 229960004275 glycolic acid Drugs 0.000 claims description 4
- 229960003471 retinol Drugs 0.000 claims description 4
- 235000020944 retinol Nutrition 0.000 claims description 4
- 239000011607 retinol Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 102000045756 human TRPV1 Human genes 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 38
- 239000000126 substance Substances 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 2
- 238000011002 quantification Methods 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 57
- 239000000284 extract Substances 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 241000675108 Citrus tangerina Species 0.000 description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
- 240000000425 Chaenomeles speciosa Species 0.000 description 7
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 230000007794 irritation Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 4
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 4
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 4
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 4
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 4
- 229940025878 hesperidin Drugs 0.000 description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 3
- 229950011318 cannabidiol Drugs 0.000 description 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000028771 Facial injury Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
刺激物 | 浓度1 | 浓度2 | 浓度3 | 浓度4 | 浓度5 |
苯氧乙醇 | 0.0wt% | 0.3wt% | 0.5wt% | 1.0wt% | - |
DL-乳酸 | 0.0wt% | 0.5wt% | 2.0wt% | 4.0wt% | 8.0wt% |
辣椒素 | 1.25μM | 2.5μM | 5μM | 10μM | 20μM |
水杨酸 | 0.0wt% | 0.5wt% | 1.0wt% | 2.0wt% | 4.0wt% |
视黄酸 | 0.05wt% | 0.10wt% | 0.20wt% | 0.25wt% | 0.30wt% |
羟基乙酸 | 0.31wt% | 0.63wt% | 1.25wt% | 2.50wt% | 5.00wt% |
烟酰胺 | 0.31wt% | 0.63wt% | 1.25wt% | 2.50wt% | 5.00wt% |
刺激物 | 浓度 | 荧光值 | 荧光值差值 |
未处理组 | - | 20.74 | 0 |
水杨酸 | 1wt% | 66.28 | 45.53 |
视黄酸 | 0.2wt% | 76.05 | 55.31 |
羟基乙酸 | 1.25wt% | 60.43 | 39.69 |
烟酰胺 | 1.25wt% | 135.94 | 115.19 |
苯氧乙醇 | 0.5wt% | 81.37 | 60.63 |
DL-乳酸 | 2wt% | 69.13 | 48.39 |
辣椒素 | 5μM | 105.61 | 84.87 |
处理组 | 0min | 2.5min | 5min |
5%乳酸 | 2.32 | 3.15 | 3.50 |
5%乳酸+0.5%青皮提取物 | 2.55 | 1.18 | 0.91 |
5%乳酸+1%青皮提取物 | 2.29 | 0.95 | 0.73 |
5%乳酸+2%青皮提取物 | 2.41 | 0.72 | 0.45 |
5%乳酸+0.5%皱皮木瓜提取物 | 2.34 | 1.27 | 1.10 |
5%乳酸+2%皱皮木瓜提取物 | 2.42 | 0.88 | 0.53 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011402345.1A CN112626163B (zh) | 2020-12-02 | 2020-12-02 | 一种评价敏感皮肤不适感的细胞学方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011402345.1A CN112626163B (zh) | 2020-12-02 | 2020-12-02 | 一种评价敏感皮肤不适感的细胞学方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112626163A CN112626163A (zh) | 2021-04-09 |
CN112626163B true CN112626163B (zh) | 2023-03-28 |
Family
ID=75308260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011402345.1A Active CN112626163B (zh) | 2020-12-02 | 2020-12-02 | 一种评价敏感皮肤不适感的细胞学方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112626163B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102747128A (zh) * | 2012-05-24 | 2012-10-24 | 北京海威磐石生物医药科技有限公司 | Trpv3通道蛋白在筛选用于皮肤病治疗或皮肤护理的药物中的应用 |
CN111979289A (zh) * | 2020-07-22 | 2020-11-24 | 上海珈蓓生物科技有限公司 | 植提物抵抗皮肤化学性刺激的细胞学评价方法及其应用 |
-
2020
- 2020-12-02 CN CN202011402345.1A patent/CN112626163B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102747128A (zh) * | 2012-05-24 | 2012-10-24 | 北京海威磐石生物医药科技有限公司 | Trpv3通道蛋白在筛选用于皮肤病治疗或皮肤护理的药物中的应用 |
CN111979289A (zh) * | 2020-07-22 | 2020-11-24 | 上海珈蓓生物科技有限公司 | 植提物抵抗皮肤化学性刺激的细胞学评价方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112626163A (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Buhé et al. | Pathophysiological study of sensitive skin | |
McKhann et al. | Heterogeneity of astrocyte resting membrane potentials and intercellular coupling revealed by whole-cell and gramicidin-perforated patch recordings from cultured neocortical and hippocampal slice astrocytes | |
Fischer et al. | Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro | |
Davenport et al. | Effects of pH buffering on horizontal and ganglion cell light responses in primate retina: evidence for the proton hypothesis of surround formation | |
Ryall et al. | β2‐Agonist administration reverses muscle wasting and improves muscle function in aged rats | |
JP5872158B2 (ja) | 皮膚美白方法、並びに、皮膚シミ形成抑制及び/又は除去因子のスクリーニング方法 | |
Itagaki et al. | An in vitro alternative to the draize eye-irritation test: Evaluation of the crystal violet staining method | |
Liu et al. | Role of an inward rectifier K+ current and of hyperpolarization in human myoblast fusion | |
CN106822153A (zh) | 用于抑制肌萎缩的方法 | |
Leão et al. | Medial septal dysfunction by Aβ-induced KCNQ channel-block in glutamatergic neurons | |
Jabba et al. | Antillatoxin, a novel lipopeptide, enhances neurite outgrowth in immature cerebrocortical neurons through activation of voltage-gated sodium channels | |
Glogauer et al. | Introduction of large molecules into viable fibroblasts by electroporation: optimization of loading and identification of labeled cellular compartments | |
Chen et al. | Extracellular pH modulates GABAergic neurotransmission in rat hypothalamus | |
Sui et al. | The electrophysiological properties of cultured and freshly isolated detrusor smooth muscle cells | |
CN112626163B (zh) | 一种评价敏感皮肤不适感的细胞学方法 | |
Oliveira et al. | Short Time Exposure (STE) test in conjunction with Bovine Corneal Opacity and Permeability (BCOP) assay including histopathology to evaluate correspondence with the Globally Harmonized System (GHS) eye irritation classification of textile dyes | |
Sui et al. | The association between T‐type Ca2+ current and outward current in isolated human detrusor cells from stable and overactive bladders | |
Booth | An examination of college GPA, composite ACT scores, IQs, and gender in relation to loneliness of college students | |
Venugobal et al. | Brief, weekly magnetic muscle therapy improves mobility and lean body mass in older adults: A Southeast Asia community case study | |
CN109966512A (zh) | 一种用于检测敏感皮肤的面膜及其应用 | |
Zhou et al. | Modulation of TRPV1 function by Citrus reticulata (tangerine) fruit extract for the treatment of sensitive skin | |
Hu et al. | Changes of synaptic ultrastructure in the guinea pig interpositus nuclei associate with response magnitude and timing after trace eyeblink conditioning | |
Gandham et al. | Striatal cholinergic interneuron numbers are increased in a rodent model of dystonic cerebral palsy | |
Bockhorst et al. | A quantitative analysis of cortical spreading depression events in the feline brain characterized with diffusion‐weighted MRI | |
Hara et al. | A molecular technique for detecting the liberation of intracellular zinc in cultured neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201500 building 6, no.857 Tiangong Road, Jinshan District, Shanghai Applicant after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 building 6, no.857 Tiangong Road, Jinshan District, Shanghai Applicant before: SHANGHAI JIAKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 818 Tiangong Road, Jinshan District, Shanghai, 200540 Patentee after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 building 6, no.857 Tiangong Road, Jinshan District, Shanghai Patentee before: Shanghai Jiakai Biological Co.,Ltd. |